ORBIMED ADVISORS LLC 13D/13G Filings for Corvus Pharmaceuticals, Inc. (CRVS)

ORBIMED ADVISORS LLC 13D and 13G filings for Corvus Pharmaceuticals, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportView
2026-01-27
8:38 pm
Sale
2026-01-2313DCORVUS PHARMACEUTICALS INC
CRVS
ORBIMED ADVISORS LLC8,609,091
10.300%
-1,176,332decrease
(-12.02%)
Filing
2025-05-14
8:49 pm
Unchanged
2025-05-1213DCORVUS PHARMACEUTICALS INC
CRVS
ORBIMED ADVISORS LLC9,785,423
12.200%
0
(Unchanged)
Filing
2025-05-01
9:20 pm
Purchase
2025-04-2913DCORVUS PHARMACEUTICALS INC
CRVS
ORBIMED ADVISORS LLC9,785,423
13.800%
2,841,769increase
(+40.93%)
Filing
2024-05-08
7:55 pm
Unchanged
2024-05-0613DCORVUS PHARMACEUTICALS INC
CRVS
ORBIMED ADVISORS LLC6,943,654
11.100%
0
(Unchanged)
Filing
2021-11-03
3:03 pm
Unchanged
2021-11-0213DCORVUS PHARMACEUTICALS INC
CRVS
ORBIMED ADVISORS LLC6,943,654
14.900%
0
(Unchanged)
Filing
2021-09-22
5:21 pm
Sale
2021-09-2013DCORVUS PHARMACEUTICALS INC
CRVS
ORBIMED ADVISORS LLC6,943,654
16.400%
-1,109,644decrease
(-13.78%)
Filing
2021-08-04
5:21 pm
Unchanged
2021-08-0213DCORVUS PHARMACEUTICALS INC
CRVS
ORBIMED ADVISORS LLC8,053,298
19.000%
0
(Unchanged)
Filing